I was impressed by today's presentation as more data was offered, along with some excellent postives from the replication of the Euphas phase II study ( terminated at patient 64 of 128 due to extreme efficacy ).  Multiple times Prof..Antonelli mentioned the most successful Euphas study and noted the Euphrates had performed in similar fashion.  One piece of new data today reflects a most impressive 15% absolute efficacy on a subgroup of 154 patients ( I have asked a nurse to explain to me - will report back ).  I was also impressed with an additional bit of information offered on the global frequency of the "non-culturable bacteria" group.  The professor showed that in cases of Septic Shock, where no bacteria were present, we achieved a 21% absolute benefit.  He later added that this group represents a "minimum of 30%" of Septic Shock cases.  I will ask MM to complete this canvas, as I am not aware of the global opportunity $ to price the 30% market.  I was assuming that 30% of this market would still be very substantial.  

The "safety thing" was kind of comforting too.  With us treating over 150,000 patients, and having 7500+ patients run in clinical studies, along with 150+ published papers, you do run the very real risk of a "safety issue" ( throat clear ).  Seems we're pretty safe, like "stupid safe".  Shirley we've all heard commercials for a very wide range of approved drugs.  The list of side effects is endless.   Now take a look at our diagnostic guided, theranostic, state-of-the-art treatment, that would seem as safe as aspirin.

 I've always admired world class swimmers because they usually seemed to peak right before the olympics or worlds.  The science is building here folks, and I feel like PMX can still be fine tuned so it makes the podium for efficacy.  The diagnostic is key, try building a shed without a tape measure.  I always remember Square saying, "the EAA is the Lufkin of endotoxin measurement".  Let's see if our diagnostic can continue to shave small, but meaningful % points off very findable subgroups of Septic Shock patients.


Cheers,
Jorge